Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy - PubMed (original) (raw)
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy
B M Chen et al. Gynecol Oncol. 2000 Nov.
Abstract
Objective: The aim of this study was to determine whether the activity of topoisomerase I (topo I), the target of the anti-neoplastic drug camptothecin (CPT), is elevated in cervical cancer and whether CPT can radiosensitize cervical tumors.
Methods: The topo I activity of 11 normal cervix and 30 cervical carcinoma tumors was assayed by measuring the relaxation of supercoiled DNA. Subconfluent or postconfluent CaSki human cervical carcinoma cells were exposed to CPT (1-5000 ng/ml) and immediately X-irradiated (0-800 cGy). Cell survival was determined by clonogenic assay.
Results: Mean topo I activity in cervical cancer (3.0 +/- 0.06 h(-1)) was significantly greater than in normal cervix tissue (0.29 +/- 0.06 h(-1)). Stage 3 and 4 cervical carcinoma specimens displayed a trend of greater topo I activity (5.88 +/- 3.7 h(-1)) than stage 1 and 2 tumors (2.57 +/- 0.47 h(-1)). No correlation between topo I protein levels and catalytic activity was found. Combined treatment of subconfluent CaSki cells with CPT and ionizing radiation resulted in additive killing of cells. Combined treatment of postconfluent CaSki cells with low doses of radiation (200 and 400 cGy) and 1 or 10 ng/ml CPT for 2 or 48 h produced significant cytotoxicity compared to CPT or radiation alone, which were ineffective at these doses.
Conclusions: Topo I activity is elevated in cervical cancer compared to normal cervix. The radiosensitivity of noncycling cells within cervical tumors may be increased by simultaneous treatment with low doses of CPT or other topo I inhibitors.
Copyright 2000 Academic Press.
Similar articles
- Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y. Gupta M, et al. Clin Cancer Res. 1997 Sep;3(9):1653-60. Clin Cancer Res. 1997. PMID: 9815856 - Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Davis PL, et al. Anticancer Res. 1998 Jul-Aug;18(4C):2919-32. Anticancer Res. 1998. PMID: 9713486 - Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors.
Lamond JP, Wang M, Kinsella TJ, Boothman DA. Lamond JP, et al. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):369-76. doi: 10.1016/s0360-3016(96)00326-4. Int J Radiat Oncol Biol Phys. 1996. PMID: 8892462 Review.
Cited by
- The Antibacterial Activity and Mechanism of Action of Luteolin Against Trueperella pyogenes.
Guo Y, Liu Y, Zhang Z, Chen M, Zhang D, Tian C, Liu M, Jiang G. Guo Y, et al. Infect Drug Resist. 2020 Jun 10;13:1697-1711. doi: 10.2147/IDR.S253363. eCollection 2020. Infect Drug Resist. 2020. PMID: 32606820 Free PMC article. - Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.
Zhang F, Rothermund K, Gangadharan SB, Pommier Y, Prochownik EV, Lazo JS. Zhang F, et al. Oncotarget. 2012 Sep;3(9):998-1010. doi: 10.18632/oncotarget.632. Oncotarget. 2012. PMID: 22948175 Free PMC article. - Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D. Dueñas-González A, et al. Drugs. 2010 Mar 5;70(4):403-32. doi: 10.2165/11534370-000000000-00000. Drugs. 2010. PMID: 20205484 Review. - Radiosensitizers in cervical cancer. Cisplatin and beyond.
Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Candelaria M, et al. Radiat Oncol. 2006 May 8;1:15. doi: 10.1186/1748-717X-1-15. Radiat Oncol. 2006. PMID: 16722549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical